A severe limitation for cancer therapy is the poor water solubility of many important therapeutic anticancer drugs. The development of novel delivery systems is therefore currently ongoing. We propose the use of β-cyclodextrin based nanosponges to deliver paclitaxel as an alternative to classical formulation in Cremophor EL. They are solid nanoparticles with mean diameter lower than 500 nm and spherical shape. Nanosponges show a safe profile being non-hemolytic and non cytotoxic. Nanosponges dissolved and encapsulated paclitaxel up to 2 mg/ml. The paclitaxel-loaded nanosponges formed a water stable colloidal system avoiding the recrystallization of paclitaxel. The in vitro release studies showed an almost complete release in 2 h without initial burst effect. Our study demonstrates that delivery of paclitaxel via nanosponges increased the amount of paclitaxel entering cancer cells and lowers paclitaxel IC50, therefore enhancing its pharmacological effect. β-Cyclodextrin based nanosponges can therefore be considered an alternative system to solubilize and deliver the paclitaxel.

In vitro enhancement of anticancer activity of paclitaxel by a Cremophor free cyclodextrin-based nanosponge formulation

MOGNETTI, Barbara;BARBERIS, ALESSANDRO;MARINO, SILVIA;BERTA, Giovanni Nicolao;DE FRANCIA, SILVIA;TROTTA, Francesco;CAVALLI, Roberta
2012-01-01

Abstract

A severe limitation for cancer therapy is the poor water solubility of many important therapeutic anticancer drugs. The development of novel delivery systems is therefore currently ongoing. We propose the use of β-cyclodextrin based nanosponges to deliver paclitaxel as an alternative to classical formulation in Cremophor EL. They are solid nanoparticles with mean diameter lower than 500 nm and spherical shape. Nanosponges show a safe profile being non-hemolytic and non cytotoxic. Nanosponges dissolved and encapsulated paclitaxel up to 2 mg/ml. The paclitaxel-loaded nanosponges formed a water stable colloidal system avoiding the recrystallization of paclitaxel. The in vitro release studies showed an almost complete release in 2 h without initial burst effect. Our study demonstrates that delivery of paclitaxel via nanosponges increased the amount of paclitaxel entering cancer cells and lowers paclitaxel IC50, therefore enhancing its pharmacological effect. β-Cyclodextrin based nanosponges can therefore be considered an alternative system to solubilize and deliver the paclitaxel.
2012
74
1-4
201
210
anticancer agents; Drug delivery; Nanosponges; Paclitaxel; β-Cyclodextrin
Barbara Mognetti; Alessandro Barberis; Silvia Marino; Giovanni Berta; Silvia De Francia; Francesco Trotta; Roberta Cavalli
File in questo prodotto:
File Dimensione Formato  
Pacli e nanospugne.pdf

Accesso riservato

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 618.82 kB
Formato Adobe PDF
618.82 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/131966
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 90
  • ???jsp.display-item.citation.isi??? 79
social impact